Novo Nordisk A/S (NVO)

107.74
+1.14(+1.07%)
After Hours
106.54
-1.20(-1.11%)
- Real-time Data
  • Volume:
    908,947
  • Day's Range:
    105.60 - 107.83
  • 52 wk Range:
    78.71 - 122.16

NVO Overview

Prev. Close
106.6
Day's Range
105.6-107.83
Revenue
21.51B
Open
105.7
52 wk Range
78.71-122.16
EPS
3.1
Volume
908,947
Market Cap
242.09B
Dividend (Yield)
1.1181
(1.04%)
Average Vol. (3m)
1,503,350
P/E Ratio
34.80
Beta
0.47
1-Year Change
36.69%
Shares Outstanding
2,271,041,119
Next Earnings Date
Aug 04, 2022
What is your sentiment on Novo Nordisk ADR?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk A/S News

Novo Nordisk A/S Analysis

Novo Nordisk A/S Company Profile

Novo Nordisk A/S Company Profile

Employees
49295

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Buy
  • Novo Nordisk announced plans to invest more than 17 billion Danish kroner ($2.58 billion) in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
    0
    • sure, best company
      0
      • NVO WILL BUY ORMP AT 30 $
        0
        • and Gals..! :D
          0
          • Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
            1
            • Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
              0
            • Could be massive?? It will be now approved by FDA in US and soon EU all that remains is production cabability which was surprisingly not ready for such a demand (only US) so IMO this WILL exploded 10 fold what NN has expected., maybe more. Where do you find a obesity drug that helps? What obesity formulars has ever worked? This actually dos work.. Get ready!!!
              0
          • Very good long term investment
            0
            • Anyone got a view on how much the plans to reduce medical prices will affect the share price ?
              0
              • My bet is that the stock price will have an increase in growth on the long term. Not sure about short term as they might need to spend to expand production, however, they might get subsidies for this.
                0